Simple pseudo-dipeptides with a P2′ glutamate: A novel inhibitor family of matrix metalloproteases and other metzincins

Journal of Biological Chemistry

Volumn 287, Issue 32, 2012, Pages 26647-26656

  Devel, Laurent ^a   Beau, Fabrice ^a   Amoura, Mehdi ^a   Vera, Laura ^a   Cassar Lajeunesse, Evelyne ^a   Garcia, Sandra ^a   Czarny, Bertrand ^a   Stura, Enrico A ^a   Dive, Vincent ^a  

^a SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOHYDROXAMIC ACIDS; ACTIVE SITE; ACYL MOIETY; BINDING MODES; GLUTAMATE SIDE CHAIN; L-GLUTAMATE; L-GLUTAMINE; METALLOPROTEASES; NANOMOLAR AFFINITY; PSEUDO-PEPTIDE; SELECTIVE INHIBITORS; SIDE-CHAINS; X RAY CRYSTAL STRUCTURES; ZINC IONS;

AMINO ACIDS; BINDING ENERGY; CARBOXYLATION; X RAY CRYSTALLOGRAPHY; ZINC;

PEPTIDES;

ACETOHYDROXAMIC ACID; CARBOXYLIC ACID; GLUTAMIC ACID; MACROPHAGE ELASTASE; MACROPHAGE ELASTASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; METZINCIN; PSEUDO DIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; ZINC;

AMINO ACID COMPOSITION; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SELECTIVITY; PRIORITY JOURNAL; PROTEIN MOTIF; SOLUTION AND SOLUBILITY; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DIPEPTIDES; GLUTAMIC ACID; MATRIX METALLOPROTEINASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; SUBSTRATE SPECIFICITY;

EID: 84864560962     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.380782     Document Type: Article

References (58)

1. Bode, W. (2003) Structural basis of matrix metalloproteinase function. Biochem. Soc. Symp. 1-14
2. Tallant, C., Marrero, A., and Gomis-Rüth, F. X. (2010) Matrix metalloproteinases: Fold and function of their catalytic domains. Biochim. Biophys. Acta 1803, 20-28
3. Overall, C. M., and Kleifeld, O. (2006) Tumor microenvironment-opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6, 227-239 (Pubitemid 43292566)
4. Bäck, M., Ketelhuth, D. F., and Agewall, S. (2010) Matrix metalloproteinases in atherothrombosis. Prog. Cardiovasc. Dis. 52, 410-428
5. Kessenbrock, K., Plaks, V., and Werb, Z. (2010) Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 141, 52-67
6. Dejonckheere, E., Vandenbroucke, R. E., and Libert, C. (2011) Matrix metalloproteinases as drug targets in ischemia/reperfusion injury. Drug Discov. Today 16, 762-778
7. Lagente, V., and Boichot, E. (2010) Role of matrix metalloproteinases in the inflammatory process of respiratory diseases. J. Mol. Cell Cardiol. 48, 440-444
8. Babine, R. E., and Bender, S. L. (1997) Molecular recognition of protein-ligand complexes: Applications to drug design. Chem. Rev. 97, 1359-1472 (Pubitemid 127659602)
9. Whittaker, M., Floyd, C. D., Brown, P., and Gearing, A. J. (1999) Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99, 2735-2776
10. Cuniasse, P., Devel, L., Makaritis, A., Beau, F., Georgiadis, D., Matziari, M., Yiotakis, A., and Dive, V. (2005) Future challenges facing the development of specific active site-directed synthetic inhibitors of MMPs. Biochimie. 87, 393-402 (Pubitemid 40387619)
11. Fisher, J. F., and Mobashery, S. (2006) Recent advances in MMP inhibitor design. Cancer Metastasis Rev. 25, 115-136 (Pubitemid 43723987)
12. Nuti, E., Tuccinardi, T., and Rossello, A. (2007) Matrix metalloproteinase inhibitors: New challenges in the era of post broad spectrum inhibitors. Curr. Pharm. Des. 13, 2087-2100 (Pubitemid 47040490)
13. Tu, G., Xu, W., Huang, H., and Li, S. (2008) Progress in the development of matrix metalloproteinase inhibitors. Curr. Med. Chem. 15, 1388-1395 (Pubitemid 351997789)
14. Yiotakis, A., and Dive, V. (2008) Synthetic active site-directed inhibitors of metzincins: Achievement and perspectives. Mol. Aspects Med. 29, 329-338
15. Jacobsen, J. A., Major Jourden, J. L., Miller, M. T., and Cohen, S. M. (2010) To bind zinc or not to bind zinc: An examination of innovative approaches to improved metalloproteinase inhibition. Biochim. Biophys. Acta 1803, 72-94
16. Coussens, L. M., Fingleton, B., and Matrisian, L. M. (2002) Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295, 2387-2392 (Pubitemid 34270240)
17. Overall, C. M., and Kleifeld, O. (2006) Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 94, 941-946
18. Fingleton, B. (2007) Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Des. 13, 333-346
19. Devel, L., Czarny, B., Beau, F., Georgiadis, D., Stura, E., and Dive, V. (2010) Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1′ cavity. Biochimie. 92, 1501-1508
20. Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M., and Cravatt, B. F. (2004) Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl. Acad. Sci. U.S.A. 101, 10000-10005 (Pubitemid 38891185)
21. Devel, L., Rogakos, V., David, A., Makaritis, A., Beau, F., Cuniasse, P., Yiotakis, A., and Dive, V. (2006) Development of selective inhibitors and substrate of matrix metalloproteinase-12. J. Biol. Chem. 281, 11152-11160 (Pubitemid 43855540)
22. Li, W., Li, J., Wu, Y., Rancati, F., Vallese, S., Raveglia, L., Wu, J., Hotchandani, R., Fuller, N., Cunningham, K., Morgan, P., Fish, S., Krykbaev, R., Xu, X., Tam, S., Goldman, S. J., Abraham, W., Williams, C., Sypek, J., and Mansour, T. S. (2009) Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma. J. Med. Chem. 52, 5408-5419
23. Engel, C. K., Pirard, B., Schimanski, S., Kirsch, R., Habermann, J., Klingler, O., Schlotte, V., Weithmann, K. U., and Wendt, K. U. (2005) Structural basis for the highly selective inhibition of MMP-13. Chem. Biol. 12, 181-189 (Pubitemid 40281325)
24. Johnson, A. R., Pavlovsky, A. G., Ortwine, D. F., Prior, F., Man, C. F., Bornemeier, D. A., Banotai, C. A., Mueller, W. T., McConnell, P., Yan, C., Baragi, V., Lesch, C., Roark, W. H., Wilson, M., Datta, K., Guzman, R., Han, H. K., and Dyer, R. D. (2007) Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 (MMP13) that reduces cartilage damage in vivo without joint fibroplasia side effects. J. Biol. Chem. 282, 27781-27791 (Pubitemid 47529503)
25. Li, J. J., Nahra, J., Johnson, A. R., Bunker, A., O'Brien, P., Yue, W. S., Ortwine, D. F., Man, C. F., Baragi, V., Kilgore, K., Dyer, R. D., and Han, H. K. (2008) Quinazolinones and pyrido[3,4-D]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. J. Med. Chem. 51, 835-841 (Pubitemid 351304692)
26. Heim-Riether, A., Taylor, S. J., Liang, S., Gao, D. A., Xiong, Z., Michael August, E., Collins, B. K., Farmer, B. T., 2nd, Haverty, K., Hill-Drzewi, M., Junker, H. D., Mariana Margarit, S., Moss, N., Neumann, T., Proudfoot, J. R., Keenan, L. S., Sekul, R., Zhang, Q., Li, J., and Farrow, N. A. (2009) Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors. Bioorg. Med. Chem. Lett. 19, 5321-5324
27. Schnute, M. E., O'Brien, P. M., Nahra, J., Morris, M., Howard Roark, W., Hanau, C. E., Ruminski, P. G., Scholten, J. A., Fletcher, T. R., Hamper, B. C., Carroll, J. N., Patt, W. C., Shieh, H. S., Collins, B., Pavlovsky, A. G., Palmquist, K. E., Aston, K. W., Hitchcock, J., Rogers, M. D., McDonald, J., Johnson, A. R., Munie, G. E., Wittwer, A. J., Man, C. F., Settle, S. L., Nemirovskiy, O., Vickery, L. E., Agawal, A., Dyer, R. D., and Sunyer, T. (2010) Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg. Med. Chem. Lett. 20, 576-580
28. Gao, D. A., Xiong, Z., Heim-Riether, A., Amodeo, L., August, E. M., Cao, X., Ciccarelli, L., Collins, B. K., Harrington, K., Haverty, K., Hill-Drzewi, M., Li, X., Liang, S., Margarit, S. M., Moss, N., Nagaraja, N., Proudfoot, J., Roman, R., Schlyer, S., Keenan, L. S., Taylor, S., Wellenzohn, B., Wiedenmayer, D., Li, J., and Farrow, N. A. (2010) SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability. Bioorg. Med. Chem. Lett. 20, 5039-5043
29. Roth, J., Minond, D., Darout, E., Liu, Q., Lauer, J., Hodder, P., Fields, G. B., and Roush, W. R. (2011) Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. Bioorg. Med. Chem. Lett. 21, 7180-7184
30. De Savi, C., Morley, A. D., Ting, A., Nash, I., Karabelas, K., Wood, C. M., James, M., Norris, S. J., Karoutchi, G., Rankine, N., Hamlin, G., Macfaul, P. A., Ryan, D., Baker, S. V., Hargreaves, D., and Gerhardt, S. (2011) Selective non-zinc binding inhibitors of MMP13. Bioorg. Med. Chem. Lett. 21, 4215-4219
31. De Savi, C., Morley, A. D., Nash, I., Karoutchi, G., Page, K., Ting, A., and Gerhardt, S. (2012) Lead optimization of selective non-zinc binding inhibitors of MMP13. Part 2. Bioorg. Med. Chem. Lett. 22, 271-277
32. Gege, C., Bao, B., Bluhm, H., Boer, J., Gallagher, B. M., Korniski, B., Powers, T. S., Steeneck, C., Taveras, A. G., and Baragi, V. M. (2012) Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis. J. Med. Chem. 55, 709-716
33. Pochetti, G., Montanari, R., Gege, C., Chevrier, C., Taveras, A. G., and Mazza, F. (2009) Extra binding region induced by non-zinc chelating inhibitors into the S1′ subsite of matrix metalloproteinase 8 (MMP-8). J. Med. Chem. 52, 1040-1049
34. Baragi, V. M., Becher, G., Bendele, A. M., Biesinger, R., Bluhm, H., Boer, J., Deng, H., Dodd, R., Essers, M., Feuerstein, T., Gallagher, B. M., Jr., Gege, C., Hochgürtel, M., Hofmann, M., Jaworski, A., Jin, L., Kiely, A., Korniski, B., Kroth, H., Nix, D., Nolte, B., Piecha, D., Powers, T. S., Richter, F., Schneider, M., Steeneck, C., Sucholeiki, I., Taveras, A., Timmermann, A., Van Veldhuizen, J., Weik, J., Wu, X., and Xia, B. (2009) A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum. 60, 2008-2018
35. Piecha, D., Weik, J., Kheil, H., Becher, G., Timmermann, A., Jaworski, A., Burger, M., and Hofmann, M. W. (2010) Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants. Inflamm. Res. 59, 379-389
36. Quillard, T., Tesmenitsky, Y., Croce, K., Travers, R., Shvartz, E., Koskinas, K. C., Sukhova, G. K., Aikawa, E., Aikawa, M., and Libby, P. (2011) Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 31, 2464-2472
37. Johnson, J. L., Devel, L., Czarny, B., George, S. J., Jackson, C. L., Rogakos, V., Beau, F., Yiotakis, A., Newby, A. C., and Dive, V. (2011) A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E knock-out mice. Arterioscler. Thromb. Vasc. Biol. 31, 528-535
38. Devel, L., Beau, F., Czarny, B., and Dive, V. (March 3, 2011) Pseudodipeptides as MMP inhibitors, WO2011/023864
39. Devel, L., Garcia, S., Czarny, B., Beau, F., LaJeunesse, E., Vera, L., Georgiadis, D., Stura, E., and Dive, V. (2010) Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1′ loop canonical conformation. J. Biol. Chem. 285, 35900-35909
40. Dabert-Gay, A. S., Czarny, B., Devel, L., Beau, F., Lajeunesse, E., Bregant, S., Thai, R., Yiotakis, A., and Dive, V. (2008) Molecular determinants of matrix metalloproteinase-12 covalent modification by a photoaffinity probe: Insights into activity-based probe development and conformational variability of matrix metalloproteinases. J. Biol. Chem. 283, 31058-31067
41. Horovitz, A., and Levitzki, A. (1987) An accurate method for determination of receptor-ligand and enzyme-inhibitor dissociation constants from displacement curves. Proc. Natl. Acad. Sci. U.S.A. 84, 6654-6658
42. Yonetani, T. (1982) The Yonetani-Theorell graphical method for examining overlapping subsites of enzyme active centers. Methods Enzymol. 87, 500-509
43. Stura, E., and Wilson, I. (1991) Applications of the streak seeding technique in protein crystallization. J. Cryst. Growth 110, 210-282
44. Stura, E. A., and Wilson, I. A. (1992) Strategies in the crystallization of glycoproteiens and protein complexes. J. Cryst. Growth 122, 273-285
45. Holmes, I. P., Gaines, S., Watson, S. P., Lorthioir, O., Walker, A., Baddeley, S. J., Herbert, S., Egan, D., Convery, M. A., Singh, O. M., Gross, J. W., Strelow, J. M., Smith, R. H., Amour, A. J., Brown, D., and Martin, S. L. (2009) The identification of β-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg. Med. Chem. Lett. 19, 5760-5763
46. Kabsch, W. (2010) XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132
47. Leslie, A. G. (2006) The integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 62, 48-57
48. Collaborative Computational Project, Number 4 (1994) The CCP4 suite: Programs for protein crystallography. Acta Crystallogr.DBiol. Crystallogr. 50, 760-763
49. Morales, R., Perrier, S., Florent, J. M., Beltra, J., Dufour, S., De Mendez, I., Manceau, P., Tertre, A., Moreau, F., Compere, D., Dublanchet, A. C., and O'Gara, M. (2004) Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. J. Mol. Biol. 341, 1063-1076 (Pubitemid 39043656)
50. Vagin, A., and Teplyakov, A. (1997) MOLREP: An automated program for molecular replacement. J. Appl. Cryst. 30, 1022-1025 (Pubitemid 127485985)
51. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (Pubitemid 27235885)
52. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501
53. Moriarty, N. W., Grosse-Kunstleve, R. W., and Adams, P. D. (2009) electronic Ligand Builder and Optimization Workbench (eLBOW): A tool for ligand coordinate and restraint generation. Acta Crystallogr. D Biol. Crystallogr. 65, 1074-1080
54. Bertini, I., Calderone, V., Fragai, M., Luchinat, C., Maletta, M., and Yeo, K. J. (2006) Snapshots of the reaction mechanism of matrix metalloproteinases. Angew Chem. Int. Ed Engl. 45, 7952-7955 (Pubitemid 44912749)
55. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (Pubitemid 47080256)
56. DeLano, W. L. (2010) The PyMOL Molecular Graphics System, version 1.3r1, Schrödinger, LLC, New York
57. Bertini, I., Calderone, V., Cosenza, M., Fragai, M., Lee, Y. M., Luchinat, C., Mangani, S., Terni, B., and Turano, P. (2005) Conformational variability of matrix metalloproteinases: Beyond a single 3D structure. Proc. Natl. Acad. Sci. U.S.A. 102, 5334-5339 (Pubitemid 40530258)
58. Gomis-Rüth, F. X. (2009) Catalytic domain architecture of metzincin metalloproteases. J. Biol. Chem. 284, 15353-15357